DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases

Vilmos Fulop, Cristiano V. Colitti, David Genest, Ross S. Berkowitz, Gary K. Yiu, Shu Wing Ng, Janos Szepesi, Samuel C. Mok

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Gestational trophoblastic diseases comprise a spectrum of interrelated diseases including partial mole, complete mole and gestational choriocarcinoma. Using reverse transcriptase PCR (RT-PCR) analysis, we identified higher levels of DOC-2/hDab2 expression in the normal trophoblast cells in culture than in choriocarcinoma cell lines. Subsequent study using immunohistochemistry showed high levels of DOC-2/hDab2 protein expression in normal trophoblast tissues but significantly lower levels of expression in gestational trophoblastic disease tissues, particularly in complete mole and choriocarcinoma. When DOC-2/hDab2 was transfected into the choriocarcinoma cell lines, Jar, JEG and BeWo, the stable transfectants showed significantly reduced growth rate in culture. These data suggest that down regulation of DOC-2/hDab2 may play an important role in the development of gestational trophoblastic diseases.

Original languageEnglish
Pages (from-to)419-424
Number of pages6
JournalOncogene
Volume17
Issue number4
DOIs
Publication statusPublished - Jul 30 1998

Keywords

  • Cancer
  • DOC-2
  • Dab2
  • Trophoblastic diseases
  • Tumor suppressor

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases'. Together they form a unique fingerprint.

  • Cite this

    Fulop, V., Colitti, C. V., Genest, D., Berkowitz, R. S., Yiu, G. K., Ng, S. W., Szepesi, J., & Mok, S. C. (1998). DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene, 17(4), 419-424. https://doi.org/10.1038/sj.onc.1201955